Fennec Pharmaceuticals Inc. (FENC)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Jeffrey S. Hackman
|
CEO & Director | 632.18k | -- | 1963 |
|
Mr. Robert C. Andrade
|
Chief Financial Officer | 552.65k | -- | 1975 |
|
Dr. Pierre S. Sayad M.S., Ph.D.
|
Chief Medical Officer | 464.08k | -- | -- |
|
Mr. Terry Evans
|
Chief Commercial Officer | -- | -- | -- |
|
Ms. Christiana Cioffi M.B.A.
|
Chief Strategy Officer | -- | -- | -- |
|
Mr. Mark Gowland
|
Controller | -- | -- | -- |
|
Mr. Lei Fang
|
President of Pharstat Inc | -- | -- | -- |
Fennec Pharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 35
Description
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Corporate Governance
Upcoming Events
November 12, 2026 at 1:30 PM UTC
Fennec Pharmaceuticals Inc. Earnings Date
